Hippo pathway deficiency and recovery from heart failure after myocardial infarction: potential implications for kidney disease

Cardiac myocytes, like kidney podocytes, have a limited capacity to regenerate, and myocyte injury and loss contribute to cardiac fibrosis, pathologic remodeling, and heart failure. The paucity of therapeutic options to address heart failure and chronic kidney disease has drawn attention to the role of the Hippo pathway and its downstream effector Yes-associated protein (YAP) in both the heart and kidney. Ongoing clinical trials of a small molecule YAP inhibitor as adjunctive therapy for several common cancers further highlight the importance of understanding the role of this pathway.
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: Nephrology Digest Source Type: research